
Monarch Cement's 40% rally has pushed its P/E to 14, above the historical 10-12 range. Insider selling and slowing cement shipments raise questions about the valuation.
Monarch Cement (OTCMKTS:MCEM) has surged roughly 40% over the past year, leaving some analysts questioning whether the run has overshot the fundamentals. The company, which operates a single plant in Humboldt, Kansas, reported 2024 revenue of $305 million and net income of $87 million. At the current price near $350, the stock trades at roughly 14 times trailing earnings.
That multiple looks stretched against historical averages. Monarch has typically traded at 10 to 12 times earnings, partly because of limited liquidity and zero analyst coverage. The stock's thin float – roughly 5.7 million shares, with insiders controlling a majority – amplifies moves in either direction.
Volume has picked up in recent weeks. Daily turnover averaged about 12,000 shares in March, up from 7,000 in the fourth quarter. The buying has pushed the stock into territory where insiders have historically sold. The last insider sale came in January, when a director disposed of 2,500 shares at $340.
Monarch's earnings are tied closely to Midwest construction activity. Cement shipments fell 3% in 2024, reflecting a slowdown in nonresidential building. The company said in its annual report that it expects flat volumes in 2025.
A sustained price above $350 would put the stock at the highest valuation since 2021, when cement demand was peaking on post-pandemic infrastructure spending. That cycle ended with a 25% pullback over the following 18 months.
Monarch has no debt and carries $120 million in cash, giving it a net cash position of roughly $21 per share. That provides a floor but does not justify the current premium, several analysts said.
The company reports first-quarter results in mid-May.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.